Vizsla Copper Corp. (TSX.V: VCU, OTCQB: VCUFF) ("Vizsla Copper" or the "Company") is pleased to announce that it has entered ...
Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 ...